The CEO of Novo Nordisk plans to blame drug middlemen for the high cost of popular diabetes and weight loss drugs Ozempic and Wegovy during a Senate hearing Wednesday ...

Novo Nordisk’s CEO testified Tuesday that the company has little control over what patients pay for its blockbuster diabetes and weight-loss drugs as skeptical senators criticized the Danish ...

Sept 23 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's ...

After circling Novo Nordisk and its high GLP-1 drug prices for months, Sen. Bernie Sanders, I-Vermont, and the Senate Health, Education, Labor and Pensions (HELP) committee will soon get their ...

In today’s hearing, however, Senator Bernie Sanders put the focus on the maker of the medicine, Novo Nordisk. What’s more he said those same three PBM firms had committed to him that they ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Sen. Bernie Sanders, I-Vt. called the hearing after learning that Americans pay $969 for the weight loss and diabetes drug Ozemic — but Novo Nordisk charges $155 for the same drug in Canada and only ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...